Literature DB >> 2537696

Quinolone antimicrobial agents: mechanism of action and resistance development.

L E Bryan1, J Bedard, S Wong, S Chamberland.   

Abstract

The primary target of fluoroquinolone antimicrobial agents is the A subunit of DNA gyrase. In several cases a close relationship to ID50 (inhibitory dose-50%) and minimum inhibitory concentration (MIC) has been shown for gram-negative bacteria, although this has not been regularly observed for gram-positive bacteria to date. Cellular entry is by means of diffusion and involves, at least in part, the porin pathway in the outer membrane of gram-negative bacteria. An energy dependent efflux occurs which is more active in brain heart infusion broth than nutrient broth and which, to date, has not been shown to contribute to inhibition of growth or bacterial lethality. The extent of uptake by different gram-negative bacteria varies and may contribute in some cases to determination of the MIC. Resistance to fluoroquinolones is by means of mutations affecting the gyrase gene coding for the A subunit and mutations which affect cell permeability particularly involving porin proteins of the outer membrane. Combined target and permeability resistance has been reported but involves two or more mutational steps. Resistance during clinical treatment has been observed, but is most likely to be of low magnitude and to be detected in patients with significantly compromised host defenses.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537696

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  15 in total

1.  Gingival fluid ciprofloxacin levels at healthy and inflamed human periodontal sites.

Authors:  T B Conway; F M Beck; J D Walters
Journal:  J Periodontol       Date:  2000-09       Impact factor: 6.993

2.  Selective enhancement of synthesis of interleukin-2 in lymphocytes in the presence of ciprofloxacin.

Authors:  K Riesbeck; A Forsgren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

3.  Urban effluent discharges as causes of public and environmental health concerns in South Africa's aquatic milieu.

Authors:  Timothy Sibanda; Ramganesh Selvarajan; Memory Tekere
Journal:  Environ Sci Pollut Res Int       Date:  2015-09-26       Impact factor: 4.223

4.  Protective effects of local administration of ciprofloxacin on the risk of pneumococcal meningitis after cochlear implantation.

Authors:  Benjamin P C Wei; Roy M Robins-Browne; Robert K Shepherd; Kristy Azzopardi; Graeme M Clark; Stephen J O'Leary
Journal:  Laryngoscope       Date:  2006-12       Impact factor: 3.325

5.  Interaction of the fluoroquinolone antimicrobial agents ciprofloxacin and enoxacin with liposomes.

Authors:  J Bedard; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  An in vitro model of ciprofloxacin and minocycline transport by oral epithelial cells.

Authors:  James J Brayton; Qing Yang; Robin J Nakkula; John D Walters
Journal:  J Periodontol       Date:  2002-11       Impact factor: 6.993

7.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

Review 8.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Contribution of permeability and sensitivity to inhibition of DNA synthesis in determining susceptibilities of Escherichia coli, Pseudomonas aeruginosa, and Alcaligenes faecalis to ciprofloxacin.

Authors:  J Bedard; S Chamberland; S Wong; T Schollaardt; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 10.  Bacterial resistance to fluoroquinolones: lessons to be learned.

Authors:  P Ball
Journal:  Infection       Date:  1994       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.